Evidence map›Paper›PMID 30275434›Full record

ReviewNutrients2018

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target.

Manuel H Janeiro, María J Ramírez, Fermin I Milagro, J Alfredo Martínez, Maite Solas

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04510324 (Plant-Based Meat vs Animal "Red" Meat), which is not on this map. Cited by 362 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
362citing papers in PubMed, 10 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04510324 nacompletednot on this mapstarted 2020, after this paper: background citation

Plant-Based Meat vs Animal "Red" Meat: a Randomized Cross-over Trial

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2020 to 2023Enrolled41ConditionsInflammatory ResponseArmsRed meat patties group, Plant-based patties group
3 · Its place in the literature

Who cites it

362 citing papers in PubMed, 10 syntheses or guidelines pooled it, 606 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. The gut-heart axis in cardio-oncology.Cardiovascular research · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Article

302 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Manuel H JaneiroDepartment of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain. mjaneiro@alumni.unav.es.
María J RamírezDepartment of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain. mariaja@unav.es.
Fermin I MilagroDepartment of Nutrition, Food Science and Physiology, Centre for Nutrition Research, University of Navarra, 31008 Pamplona, Spain. fmilagro@unav.es.ORCID 0000-0002-3228-9916
J Alfredo MartínezDepartment of Nutrition, Food Science and Physiology, Centre for Nutrition Research, University of Navarra, 31008 Pamplona, Spain. jalfmtz@unav.es.ORCID 0000-0001-5218-6941
Maite SolasDepartment of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain. msolaszu@unav.es.
Navarre Institute of Health Research · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trimethylamine N-oxide (TMAO) is a molecule generated from choline, betaine, and carnitine via gut microbial metabolism. The plasma level of TMAO is determined by several factors including diet, gut microbial flora, drug administration and liver flavin monooxygenase activity. In humans, recent clinical studies evidence a positive correlation between elevated plasma levels of TMAO and an increased risk for major adverse cardiovascular events. A direct correlation between increased TMAO levels and neurological disorders has been also hypothesized. Several therapeutic strategies are being explored to reduce TMAO levels, including use of oral broad spectrum antibiotics, promoting the growth of bacteria that use TMAO as substrate and the development of target-specific molecules. Despite the accumulating evidence, it is questioned whether TMAO is the mediator of a bystander in the disease process. Thus, it is important to undertake studies to establish the role of TMAO in human health and disease. In this article, we reviewed dietary sources and metabolic pathways of TMAO, as well as screened the studies suggesting possible involvement of TMAO in the etiology of cardiovascular and neurological disorders, underlying the importance of TMAO mediating inflammatory processes. Finally, the potential utility of TMAO as therapeutic target is also analyzed.

Indexed as

BiomarkersCardiovascular DiseasesHumansInflammation MediatorsMetabolic Networks and PathwaysMethylaminesMolecular Targeted TherapyNervous System DiseasesBiomarkersInflammation MediatorsMethylaminestrimethyloxamineantibioticscardiovascular diseasegut dysbiosisinflammationmicrobiotaneurological disorder

Identifiers

PMID30275434
PMCPMC6213249
OpenAlexW2892844483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.